All In Biotech

Drug Trial Radar · NCT03692715

Antibiotic Prophylaxis Before Shock Wave Lithotripsy

A Multicenter Randomized Controlled Trial Assessing the Efficacy of Antimicrobial Prophylaxis for Extracorporeal Shock Wave Lithotripsy on Reducing Urinary Tract Infection

Last checked: Nov 20, 2026Latest source record: Mar 28, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 1,732 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,732

Actual

Start

Sep 27, 2018

Primary completion

Dec 31, 2024

Study completion Dec 31, 2024

Sponsor

Lead sponsor
Clinical Urology and Epidemiology Working GroupGovernment (non-federal)
Sponsor type
Government (non-federal)
Collaborators
University of Helsinki; Helsinki University Central Hospital; Western University, Canada; Centre de recherche du Centre hospitalier universitaire de Sherbrooke; King Abdulaziz University; Hospital Sao Luiz; St. Petersburg State Pavlov Medical University; University Hospital, Basel, Switzerland; Tallaght University Hospital; Tabriz University of Medical Sciences; Dr Cipto Mangunkusumo General Hospital
First posted
Oct 2, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a two arm, double blind RCT comparing the use of a single dose ciprofloxacin prior to SWL to saline alone. The multicenter trial will be conducted with a pragmatic emphasis including both high volume and low volume sites internationally.

Conditions

  • Ureteral Stones
  • Ureteral Calculi
  • Nephrolithiasis

Interventions

  • CiprofloxacinDrug

    Oral or intravenous ciprofloxacin prior to shockwave lithotripsy.

  • PlaceboDrug

    identical oral placebo if oral cipro was used, or intravenous saline alone in a blinded fashion if IV cipro was used prior to shockwave lithotripsy.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Composite outcome including positive urine culture, symptoms of cystitis, pyelonephritis or urosepsisTime frame: 7-14 days post-shockwave lithotripsy

Locations

10 sites in 9 countries. Site status is shown where the registry gives one.

  • Hospital Sao Luiz

    São Paulo, Brazil

  • Western University Hospital

    London, Ontario, Canada

  • University of Sherbrooke

    Sherbrooke, Quebec, Canada

  • Helsinki University Hospital

    Helsinki, Finland

  • Universitas Indonesia - Cipto Mangunkusumo Hospital

    Jakarta, Indonesia

  • Tabriz University of Medical Science

    Tabriz, Iran

  • Tallaght University Hospital

    Dublin, Ireland

  • St Petersburg State Pavlov Medical University

    Saint Petersburg, Russia

  • King Abdulaziz University

    Jeddah, Saudi Arabia

  • Department of Urology, University Hospital Basel

    Basel, Switzerland

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.